Annovis Bio, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Annovis Bio, Inc. (ANVS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 4.30% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-21
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 4.30%, a 4.44% decline from fiscal 2023.
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 4.50%, a 18.42% increase from fiscal 2022.
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 3.80%, a 58.33% increase from fiscal 2021.
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 2.40%, a 26.32% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 4.30% 10-K · filed 2025-03-21 |
| 2023-12-31 | 4.50% 10-K · filed 2025-03-21 |
| 2022-12-31 | 3.80% 10-K · filed 2024-03-29 |
| 2021-12-31 | 2.40% 10-K · filed 2023-03-31 |
| 2020-12-31 | 1.90% 10-K · filed 2022-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |